angiotensin ii has been researched along with Tachycardia, Ventricular in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 3 (25.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, Y; Dai, Y; Jia, K; Jin, Q; Li, X; Liu, A; Lu, L; Wu, L | 1 |
| Chaudhary, AK; Ely, D; Gopinathannair, R; Martins, JB; Xing, D; Zheng, W | 1 |
| Bernstein, KE; Dolmatova, E; Dudley, SC; Duffy, HS; Gourdie, RG; Harris, BS; Iravanian, S; Jiao, Z; Lardin, HA; Liu, H; Sovari, AA; Witham, EA; Xiao, HD | 1 |
| Bernstein, KE; Bonini, MG; Dolmatova, E; Dudley, SC; Duffy, HS; Iravanian, S; Jiao, Z; Kumar, V; Liu, H; Sovari, AA; Wang, K; Zandieh, S | 1 |
| Cao, H; Hu, H; Huang, C; Huang, H; Li, H; Liu, Y; Qin, M; Wang, T | 1 |
| Delbridge, LM; Domenighetti, AA; Huggins, CE; Pedrazzini, T; Pepe, S | 1 |
| Doi, M; Kobayashi, S; Kohno, M; Matsuzaki, M; Oda, T; Ohkusa, T; Okuda, S; Tokuhisa, T; Yamamoto, T; Yano, M | 1 |
| Cornish, KG; Gao, L; Li, YL; Liu, D; Schultz, HD; Wang, W; Zucker, IH | 1 |
| Dechend, R; Dietz, R; Fiebeler, A; Fischer, R; Gapelyuk, A; Gratze, P; Gruner, A; Gruner, K; Luft, FC; Muller, DN; Qadri, F; Schirdewan, A; Shagdarsuren, E; Wellner, M | 1 |
| Karagueuzian, HS; Morita, N; Sovari, AA; Weiss, JN | 1 |
| Gondo, N; Kumagai, K; Nakashima, H; Saku, K | 1 |
| Cardin, S; Leung, TK; Li, D; Nattel, S; Pang, L; Shinagawa, K; Wang, Z | 1 |
12 other study(ies) available for angiotensin ii and Tachycardia, Ventricular
| Article | Year |
|---|---|
Senolytic Agent Navitoclax Inhibits Angiotensin II-Induced Heart Failure in Mice.
Topics: Angiotensin II; Aniline Compounds; Animals; Apoptosis; Cardiac Pacing, Artificial; Cardiomegaly; Cells, Cultured; Cellular Senescence; Disease Models, Animal; Fibrosis; Heart Failure; Inflammation Mediators; Male; Mice, Inbred C57BL; Myocytes, Cardiac; Rats, Sprague-Dawley; Stroke Volume; Sulfonamides; Tachycardia, Ventricular; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Angiotensin II effects on ischemic focal ventricular tachycardia are predominantly mediated through myocardial AT(2) receptor.
Topics: Action Potentials; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Disease Models, Animal; Dogs; Electrocardiography; Electrophysiologic Techniques, Cardiac; Endocardium; Female; Imidazoles; Infusions, Intravenous; Losartan; Male; Myocardial Ischemia; Myocardium; Purkinje Fibers; Pyridines; Receptor, Angiotensin, Type 2; Signal Transduction; Tachycardia, Ventricular; Time Factors | 2009 |
Inhibition of renin-angiotensin system (RAS) reduces ventricular tachycardia risk by altering connexin43.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Connexin 43; Disease Models, Animal; Electrocardiography; Female; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myocytes, Cardiac; Peptidyl-Dipeptidase A; Phosphorylation; Renin-Angiotensin System; Risk; Tachycardia, Ventricular | 2011 |
Inhibition of c-Src tyrosine kinase prevents angiotensin II-mediated connexin-43 remodeling and sudden cardiac death.
Topics: Angiotensin II; Animals; Blotting, Western; Connexin 43; CSK Tyrosine-Protein Kinase; Death, Sudden, Cardiac; Disease Models, Animal; Enzyme Inhibitors; Gap Junctions; Immunohistochemistry; Mice; Mice, Transgenic; Phosphorylation; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; src-Family Kinases; Tachycardia, Ventricular; Telemetry; Ventricular Fibrillation | 2011 |
Absence of Rgs5 prolongs cardiac repolarization and predisposes to ventricular tachyarrhythmia in mice.
Topics: Action Potentials; Angiotensin II; Animals; Disease Models, Animal; Electrocardiography; Genetic Predisposition to Disease; Heart; In Vitro Techniques; Male; Mice; Mice, Knockout; Myocardium; Potassium; Potassium Channels; Receptor, Angiotensin, Type 1; RGS Proteins; Tachycardia, Ventricular | 2012 |
Elevated intracardiac angiotensin II leads to cardiac hypertrophy and mechanical dysfunction in normotensive mice.
Topics: Angiotensin II; Angiotensinogen; Animals; Blood Pressure; Cardiomegaly; Heart Rate; Mice; Mice, Transgenic; Myocardial Contraction; Myocardium; Rats; Tachycardia, Ventricular; Ventricular Remodeling | 2003 |
Valsartan restores sarcoplasmic reticulum function with no appreciable effect on resting cardiac function in pacing-induced heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Signaling; Calcium-Transporting ATPases; Cardiac Pacing, Artificial; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dobutamine; Dogs; Drug Evaluation, Preclinical; Heart Failure; Myocardial Contraction; Norepinephrine; Phosphorylation; Protein Processing, Post-Translational; Receptors, Adrenergic, beta; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum; Tachycardia, Ventricular; Tacrolimus Binding Proteins; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2004 |
Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin II and NAD(P)H oxidase.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Ditiocarb; Heart Failure; Heart Rate; Injections, Intraventricular; Kidney; Losartan; Male; Medulla Oblongata; NADPH Oxidases; Protein Subunits; Rabbits; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; RNA, Messenger; Superoxides; Sympathetic Nervous System; Tachycardia, Ventricular; Telemetry | 2004 |
Angiotensin II-induced sudden arrhythmic death and electrical remodeling.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Animals, Genetically Modified; Blood Pressure; Cardiac Pacing, Artificial; Cardiomegaly; Connexin 43; Death, Sudden, Cardiac; Disease Models, Animal; Electrocardiography; Heart Conduction System; Hypertension; Losartan; Male; Myocardium; Rats; Rats, Sprague-Dawley; Renin; RNA, Messenger; Shal Potassium Channels; Tachycardia, Ventricular; Telemetry; Time Factors; Ventricular Remodeling | 2007 |
Serum transforming growth factor-beta1 as a risk stratifier of sudden cardiac death.
Topics: Angiotensin II; Cost-Benefit Analysis; Death, Sudden, Cardiac; Fibrosis; Humans; Ions; Models, Biological; Models, Theoretical; Myocardium; Risk; Tachycardia, Ventricular; Transforming Growth Factor beta1; Ventricular Fibrillation | 2008 |
Angiotensin II provokes cesium-induced ventricular tachyarrhythmias.
Topics: Action Potentials; Analysis of Variance; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Arrhythmia Agents; Captopril; Cesium; Dogs; Electrocardiography; Enzyme Inhibitors; Estrenes; Female; Hemodynamics; Male; Models, Animal; Pyrrolidinones; Random Allocation; Tachycardia, Ventricular; Type C Phospholipases | 2001 |
Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Fibrillation; Dogs; Electrophysiology; Enalapril; Endomyocardial Fibrosis; Heart Atria; Heart Failure; Hemodynamics; Hydralazine; Isosorbide Dinitrate; Mitogen-Activated Protein Kinases; Renin-Angiotensin System; Signal Transduction; Tachycardia, Ventricular | 2001 |